American Conference Institute presents: The Comprehensive Guide to PATENT REFORM For Life Sciences Companies: The critical industry forum on the Leahy-Smith America Invents Act
*Jan. 31-Feb. 1, 2012* Flatotel * New York, NY
Attend and hear USPTO Insights and Guidance on the AIA:
Teresa Stanek Rea
Deputy Under Secretary of Commerce for Intellectual Property and Deputy
Patent Reform Coordinator, USPTO
Robert L. Stoll
Former Commissioner for Patents, USPTO
With the historic passing of The America Invents Act, H.R. 1249, the United States is now facing the most significant patent reform in more than 60 years. Patent reform is now a reality. With countless complicated nuances throughout the statute and the unknown implications of these provisions looming, patent practitioners have been left with a multitude of questions regarding the overwhelming potential ramifications of the AIA on their patent practices. One thing is clear - with so much at stake for life sciences companies, you must plan now for the changes both in effect already and on the horizon in order to protect and defend invaluable intellectual property.
The expert faculty will discuss answers to the most pressing questions facing patent practitioners resulting from the AIA including:
- What does "first to file" actually mean under the AIA requirements? Which system can you or should file under - the current first to invent or the new first to file (or both)? And how do you avoid first-to-file bubble filings before 3/15/2013?
- When can on-sale and public use activity be considered prior art? Has secret §102(f) prior art been eliminated?
- Do you need to include best mode in the application or not and what happens if you don't? Is best mode completely toothless now? How will examiners be able to address the best mode issue?
- What will be required in the PGR process? What type of discovery? Expert witnesses? How do the estoppel provisions alter your analysis of whether to engage in the PGR system?
- What estoppel provisions are associated with IPRs and how are these different from the inter partes reexamination provisions? When do you file a 3rd party parallel IPR?
- What does the prohibition to patenting human organisms actually mean for the life sciences industry?
- What qualifies as a micro-entity and how do micro entities take advantage of the new fee reduction provisions available to them? Do you need to file an IDS with prioritized examination applications?
For more Information, please visit our website: http://www.americanconference.com/patentreform